Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Bioentrepreneur
  • Published:

Planning for the exit

Nature Biotechnology volume 30, pages 132–134 (2012)Cite this article

Subjects

Abstract

As the biotech industry has matured, the exit process has evolved. Entrepreneurs need to build today's companies based on the new exit paradigm.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Author information

Authors and Affiliations

  1. Kenneth E. Eheman Jr. is a partner at Wyrick Robbins Yates & Ponton LLP, Raleigh, North Carolina, USA.,

    Kenneth E Eheman Jr

Authors
  1. Kenneth E Eheman Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenneth E Eheman Jr.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Eheman, K. Planning for the exit. Nat Biotechnol 30, 132–134 (2012). https://doi.org/10.1038/nbt.2093

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.2093

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research